Source: Hemostemix Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Hemostemix (HEM) has signed a global master services agreement with My Next Health¬†
  • The company has obtained a US$150,000 subscription from My Next Health
  • MNH has created the world’s first functional genomic AI-based tool that delivers precision medical care
  • Hemostemix will incorporate MNH’s functional genomic assays to complete an assay report
  • Next Health is a leading AI-functional-medicine-based genomic medical analysis company
  • Hemostemix Inc. (HEM) is up 7.69 per cent, trading at C$0.14 at 1:23 pm EST

Hemostemix Inc. (HEM) has signed a global master services agreement with My Next Health.

Hemostemix has also obtained a US$150,000 subscription from My Next Health at C$0.25 per unit.

My Next Health Inc. is a leading patient-based AI-functional genomic medical analysis company.

MNH is improving human health and accelerating the world’s transition to precision medicine.

From completing more than 10,000 in-person patient assessments and from its comparison of that database to 60 million patient records, MNH has created the world’s first functional genomic AI-based tool that delivers precision medical care, significantly improving an individual’s health recommendations and clinical trial outcomes.

MNH algorithms significantly impact clinical trial subject selection.

Hemostemix will incorporate MNH’s functional genomic assays to complete an assay report by an individual.

Such analyses will enable Hemostemix to recruit subjects into its clinical trials who are best suited to achieve both the safety and efficacy results desired from a randomized double-blind placebo-controlled clinical trial.

“We are pleased to partner with Hemostemix and contribute our proprietary AI-based genomic and phenotypic tools, to enhance their ground-breaking personalized stem cell therapeutics. This collaboration exemplifies the power and precision of personalized autologous medicine,” stated Dr. Richard Heinzl, CEO of MNH.

“MNH’s tools and analyses enable Hemostemix to explain when, how and why ACP works. These innovations improve the underpinnings of our therapeutics markets, and significantly de-risks our clinical trials going forward,” stated Thomas Smeenk, President & CEO of Hemostemix.

MNH is focused on improving human health and accelerating the world’s transition to precision medicine.

Hemostemix Inc. (HEM) is up 7.69 per cent, trading at C$0.14 at 1:23 pm EST.

More From The Market Herald

" BlackBerry (TSX:BB) launches Google Chrome Enterprise Management

BlackBerry (BB) has launched Chrome Enterprise Management under its UEM service.
FansUnite - CEO, Scott Burton.

" FansUnite (CSE:FANS) reports Q1 2022 financial results

FansUnite (FANS) has filed its interim financial statements for the three months ended March 31, 2022.
Converge Technology Corp - CEO, Shaun Maine

" Converge Technology (TSX:CTS) announces licensing agreement with IBM

Converge Technology (CTS) announced a licensing agreement with IBM to extend its cloud capabilities with Converge Enterprise Cloud on IBM Power for Google
Infinity Stone Ventures - CEO, Zayn Kalyan.

" Infinity Stone (CSE:GEMS) upgrades graphite at Rockstone Graphite Property

Infinity Stone Ventures (GEMS) has successfully upgraded a graphite sample from its Rockstone Graphite Property to 96.1 per cent Cg (graphitic carbon).